Completed PHASE1 INTERVENTIONAL NCT00003357

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Breast Cancer

Interventions GM2-KLH vaccine QS21

Updated 5 times since 2017 Last updated: Dec 11, 2012 Started: Jan 31, 1998 Primary completion: Nov 30, 2001 Completion: Nov 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States